Loading stock data…
BTMD
$2.19-0.03 (-1.35%)
Market ClosedLast close May 1
biote Corp.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
biote Corp. in the Healthcare sector is trading at $2.19. The stock is currently 54% below its 52-week high of $4.75, remaining 16.4% below its 200-day moving average. Technical signals show overbought RSI of 80 and bullish MACD crossover, explaining why BTMD maintains its current current market pressure. The Whystock Score of 10/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 80) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.19
Potential Upside
192%
Whystock Fair Value$6.39
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormona...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$71.14M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
3.00
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.29
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-46.20%
Volume
Today's trading volume
172,388
Recent News
GE HealthCare Technologies (GEHC) Lags Q1 Earnings Estimates
GE HealthCare (GEHC) delivered earnings and revenue surprises of -7.04% and +1.52%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
How The Investment Story For Biote (BTMD) Is Shifting With Reset Expectations And 2026 Guidance
biote’s modeled fair value has been trimmed from about US$4.21 to about US$3.17, a cut of roughly 25% that reflects a cooler view on what the shares may be worth today. Analysts link this reset to near term operational and growth headwinds, even as they point to stronger recent sales and EBITDA and ongoing investments aimed at future expansion. As you read on, you will see how this evolving narrative, from cautious guides to longer term themes, can shape the way you track biote from...
Biote Corp (BTMD) Q4 2025 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges
Biote Corp (BTMD) focuses on expanding its sales force and enhancing technology, despite facing revenue and margin pressures.
biote Corp. Q4 2025 Earnings Call Summary
Moby summary of biote Corp.'s Q4 2025 earnings call
biote Q4 Earnings Call Highlights
biote (NASDAQ:BTMD) used its fourth-quarter and full-year 2025 earnings call to outline changes made over the past year to its commercial organization and operating model, while also detailing near-term financial pressure tied to procedure trends, planned investments, and a voluntary recall at its A